Finance

Lists
Q3 2026 earnings • released • EPS beat +12,40% • Revenue miss -0,73%
See results
PRGO:NYSE
Perrigo Company PLC
USD 15,85
+0,89%
(+0,14) 1D
USD 15,85
0,00% (0,00)
After hours
Closed: 6 Nov., 16:00:04 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PRGO...
Open
USD 15,50
High
USD 15,97
Low
USD 15,25
Mkt. cap
2,20 mjd
Avg. vol.
2,59 m
Volume
2,31 m
Dividend
7,32%
Quarterly dividend
USD 0,29
Ex-dividend date
28 Aug. 2026
52-wk high
USD 16,80
52-wk low
USD 9,22
EPS
-USD 12,84
Beta
0,70
Shares outstanding
138,80 m
No. of employees
8 k
Open
USD 15,50
High
USD 15,97
Low
USD 15,25
Mkt. cap
2,20 mjd
Avg. vol.
2,59 m
Volume
2,31 m
Dividend
7,32%
Quarterly dividend
USD 0,29
Ex-dividend date
28 Aug. 2026
52-wk high
USD 16,80
52-wk low
USD 9,22
EPS
-USD 12,84
Beta
0,70
Shares outstanding
138,80 m
No. of employees
8 k
News stories
From web sources and news partners
Profile
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park. Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value. Wikipedia
About Perrigo Company PLC
CEOMurray S. Kessler
Employees8,1 k
Founded1887
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteperrigo.com
Analyst ratings
Based on 2 analysts giving stock ratings to PRGO in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for PRGO in the last 3 months.
Highest
Current USD 15,85
USD 19,00 (+19,87%)
Average
USD 17,00 (+7,26%)
Lowest
USD 15,00 (-5,36%)
Analyst
Recommendation
Action
Price target
Projected
Date
Susan Anderson
Canaccord Genuity
Buy
Reiterated
USD 19,00
+19,9%
11/05/2026
Chris Schott
J.P. Morgan
Hold
Maintained
USD 15,00
-5,4%
10/21/2026
Christine Dooley
Argus Research
Hold
Maintained
-
-
05/19/2026
Keith Devas
Jefferies
Hold
Maintained
USD 23,00
+45,1%
10/27/2025
Last report
04 Nov. 2026
Fiscal period
Q3 2026
USD 0,60 / USD 0,53
+12,40%beat
Revenue / Est. (USD)
988,60 m / 995,90 m
-0,73%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Des. 2025
Mrt. 2026
Jun. 2026
Sep. 2026
Revenue
1,11 mjd
969,20 m
1,02 mjd
988,60 m
Cost of goods sold
747,40 m
643,70 m
708,90 m
665,30 m
Cost of revenue
747,40 m
643,70 m
708,90 m
665,30 m
Research and development expenses
21,80 m
24,60 m
23,70 m
21,90 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
255,60 m
267,30 m
251,20 m
271,70 m
Operating expense
249,00 m
291,90 m
274,60 m
293,50 m
Total operating expenses
996,40 m
935,60 m
983,50 m
958,80 m
Operating income
113,20 m
33,60 m
39,30 m
29,80 m
Other non operating income
-10,70 m
3,70 m
10,10 m
-800,00 k
EBT including unusual items
-1,33 mjd
-408,60 m
105,50 m
-18,10 m
EBT excluding unusual items
68,70 m
-1,30 m
-8,50 m
-11,50 m
Income tax expense
82,90 m
-18,70 m
16,90 m
-3,80 m
Effective tax rate
-6,23%
4,58%
16,02%
20,99%
Other operating expenses
-28,40 m
-
-300,00 k
-
Net income
-1,42 mjd
-398,60 m
74,50 m
-27,50 m
Net profit margin
-127,80%
-41,13%
7,28%
-2,78%
Earnings per share
0,77
0,43
0,50
0,60
Interest and investment income
-
-
-
-
Interest expense
-52,80 m
-49,00 m
-47,00 m
-46,50 m
Net interest expenses
-52,80 m
-49,00 m
-47,00 m
-46,50 m
Depreciation and amortization charges
-
-
-
-
EBITDA
199,10 m
116,90 m
116,20 m
109,30 m
Gain or loss from assets sale
-
-
-129,50 m
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme